Título:
Impacto de la Pandemia COVID-19 en el Seguimiento y Tratamiento de los Pacientes Diabéticos
Otros títulos:
Coordinador:
Director:
Compilador:
Autor:
Giordano, Lorenzo
Pereyra, Diego
Pérez, Lucía
Suaya, Carolina
Vignolo, Emiliano
Vignolo, Nahuel
Pereyra, Diego
Pérez, Lucía
Suaya, Carolina
Vignolo, Emiliano
Vignolo, Nahuel
Tutor:
Pereda, Jimena
Piñeyro, Mercedes
Piñeyro, Mercedes
Tipo de documento:
Monografía
Editor:
Palabras clave:
Descriptores:
DIABETES MELLITUS TIPO 2
COVID-19
PANDEMIAS
EPIDEMIOLOGIA
COVID-19
PANDEMIAS
EPIDEMIOLOGIA
Año de publicación:
2021
Contenido:
Resumen:
Introducción: El objetivo de este trabajo fue conocer como ha impactado la pandemia COVID-19 en el tratamiento y seguimiento de pacientes con diabetes mellitus (DM).
Metodología: Estudio observacional, descriptivo, transversal en 39 pacientes diabéticos atendidos por Endocrinología en el Hospital de Clínicas entre julio-setiembre de 2021. Se compararon los datos antropométricos, presión arterial (PA), paraclínica (HbA1C, perfil lipídico), cambios en hábitos de alimentación, actividad física, acceso a la medicación y número de consultas previas y durante la pandemia.
Resultados: La edad media fue 61,3 ± 13 años, 56.4% mujeres. La DM2 fue la más frecuente (82,1%).
La duración media de la diabetes fue de 12,5 años (rango: 5-20). Un 84,6% tenía repercusiones microangiopáticas, la más frecuente fue la retinopatía diabética (61,5%). Un 48.7% presentaban repercusiones macroangiopáticas. Las comorbilidades más frecuentes fueron la hipertensión arterial (82,1%) y la dislipemia (69,2%). Un 18% tuvo cambios en el acceso a la mediación durante la pandemia, principalmente por falta de receta médica (12,8%). El 33% modificó su alimentación durante la pandemia, 30% aumentó la cantidad de comida, 61,5% disminuyó el consumo de frutas y verduras y el 2% aumentó el consumo de alcohol. Hubo una disminución significativa del ejercicio físico (43.6%, p=0,02), de las consultas presenciales (4.4 vs 2.9, p=0,006) y LDL (p=0,01) durante la pandemia 41% y 23% no contaban con HbA1c antes y durante la pandemia, respectivamente. La mayoría presentaban una HbA1C >7% antes y durante la pandemia (65.2% y 70%, respectivamente). El IMC, PA y HbA1c aumentaron de forma no significativa.
Conclusión: Encontramos un alto porcentaje de complicaciones micro y macroangiopáticas así como mal control metabólico con falta de monitorización de HbA1c. Observamos una disminución del control en policlínica, cambios en la alimentación, dificultades en el acceso a la medicación y una disminución del ejercicio físico durante la pandemia.
Introduction: The aim of this study was to evaluate the impact of the COVID-19 pandemic in the treatment and follow-up of patients with diabetes. Methodology: We conducted an observational, descriptive, cross-sectional study in 39 diabetic patients followed by the Endocrinology department at the Hospital de Clínicas during July-September 2021. We compared anthropometric data, blood pressure (BP), HbA1C, lipid profile, changes in eating habits, physical activity, medication access and number of medical care visits before and during the pandemic. Results: Mean age was 61.3 ± 13 years, mostly females (56.4%). Type 2 was the most common diabetes form (82.1%). Mean diabetes duration was 12.5 years (range: 5-20). Eighty-four percent had microangiopathic complications, the most frequent was diabetic retinopathy (61.5%). Forty-eight percent had macroangiopathic complications. Most frequent comorbidities were hypertension (82.1%) and dyslipidemia (69.2%). Eighteen percent had changes in medication access during the pandemic, the main reason was the lack of a medical prescription (12.8%). Thirty-three percent reported changes in eating patterns, 30% increased the amount of food consumption, 61.5% decreased the fruits and vegetables intake, and 2% increased alcohol drinking. There was a significant decrease in physical exercise (43.6%, p=0.02), medical appointments (4.4 vs. 2.9, p=0.006) and LDL (p=0.01) during the pandemic. Forty-one percent and 23% lacked hbA1C testing before and during the pandemic, respectively. Most patients presented with hbA1C values more than 7% before and after the pandemic (65.2% and 70%, respectively). There was a non signficant incrase in BMI, blood pressure and HbA1c. Conclusion: We found a high percentage of micro and microangiopathic complications in diabetic patients. In addition, many patients had poor metabolic control without HbA1c monitoring. We found a decrease in medical visits, dietary changes, disruption in medication access and a decrease in physical activities during the pandemic.
Introduction: The aim of this study was to evaluate the impact of the COVID-19 pandemic in the treatment and follow-up of patients with diabetes. Methodology: We conducted an observational, descriptive, cross-sectional study in 39 diabetic patients followed by the Endocrinology department at the Hospital de Clínicas during July-September 2021. We compared anthropometric data, blood pressure (BP), HbA1C, lipid profile, changes in eating habits, physical activity, medication access and number of medical care visits before and during the pandemic. Results: Mean age was 61.3 ± 13 years, mostly females (56.4%). Type 2 was the most common diabetes form (82.1%). Mean diabetes duration was 12.5 years (range: 5-20). Eighty-four percent had microangiopathic complications, the most frequent was diabetic retinopathy (61.5%). Forty-eight percent had macroangiopathic complications. Most frequent comorbidities were hypertension (82.1%) and dyslipidemia (69.2%). Eighteen percent had changes in medication access during the pandemic, the main reason was the lack of a medical prescription (12.8%). Thirty-three percent reported changes in eating patterns, 30% increased the amount of food consumption, 61.5% decreased the fruits and vegetables intake, and 2% increased alcohol drinking. There was a significant decrease in physical exercise (43.6%, p=0.02), medical appointments (4.4 vs. 2.9, p=0.006) and LDL (p=0.01) during the pandemic. Forty-one percent and 23% lacked hbA1C testing before and during the pandemic, respectively. Most patients presented with hbA1C values more than 7% before and after the pandemic (65.2% and 70%, respectively). There was a non signficant incrase in BMI, blood pressure and HbA1c. Conclusion: We found a high percentage of micro and microangiopathic complications in diabetic patients. In addition, many patients had poor metabolic control without HbA1c monitoring. We found a decrease in medical visits, dietary changes, disruption in medication access and a decrease in physical activities during the pandemic.
Descripción:
Editorial:
Udelar. FM
EN:
Financiadores:
Citación:
Giordano L, Pereyra D, Pérez L y otros. Impacto de la Pandemia COVID-19 en el Seguimiento y Tratamiento de los Pacientes Diabéticos [en línea]. Monografía de Pre Grado. Montevideo: Udelar. FM, 2021. 27 p.
Citación:
metadata.cc.license.name:
Documento del Gobiberno:
URI:
https://hdl.handle.net/20.500.12008/34352
ISBN:
e-ISBN:
ISSN:
ISMN:
Otros identificadores:
Título Obtenido:
Facultad o Servicio que otorga el Título:
Licencia:
Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)
Cobertura geográfica:
URUGUAY
Cobertura temporal:
2021
metadata.dc.relation.IsVersionOf:
Clasificación:
Es versión de:
Colecciones:
| Ficheros | Descripción | Tamaño | Formato | ||
|---|---|---|---|---|---|
| MCII_2021_G103.pdf | Impacto de la Pandemia COVID-19 en el Seguimiento y Tratamiento de los Pacientes Diabéticos | 677.24 KB | Adobe PDF |